Complicated Urinary Tract Infections - Pipeline Insight, 2021

SKU ID :DEL-19044456 | Published Date: 01-Sep-2021 | No. of pages: 60
Introduction Executive Summary Complicated Urinary Tract Infections: Overview • Causes • Mechanism of Action • Signs and Symptoms • Diagnosis • Disease Management Pipeline Therapeutics • Comparative Analysis Therapeutic Assessment • Assessment by Product Type • Assessment by Stage and Product Type • Assessment by Route of Administration • Assessment by Stage and Route of Administration • Assessment by Molecule Type • Assessment by Stage and Molecule Type Late Stage Products (Phase III) • Comparative Analysis Tebipenem Pivoxil Hydrobromide: Spero Therapeutics • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Mid Stage Products (Phase II) • Comparative Analysis Benapenem: Sihuan Pharmaceutical • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Early stage products (Phase I) • Comparative Analysis ETX0282CPDP: Entasis Therapeutics • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Inactive Products • Comparative Analysis Complicated Urinary Tract Infections Key Companies Complicated Urinary Tract Infections Key Products Complicated Urinary Tract Infections- Unmet Needs Complicated Urinary Tract Infections- Market Drivers and Barriers Complicated Urinary Tract Infections- Future Perspectives and Conclusion Complicated Urinary Tract Infections Analyst Views Complicated Urinary Tract Infections Key Companies Appendix
Table 1 Total Products for Complicated Urinary Tract Infections Table 2 Late Stage Products Table 3 Mid Stage Products Table 4 Early Stage Products Table 5 Pre-clinical & Discovery Stage Products Table 6 Assessment by Product Type Table 7 Assessment by Stage and Product Type Table 8 Assessment by Route of Administration Table 9 Assessment by Stage and Route of Administration Table 10 Assessment by Molecule Type Table 11 Assessment by Stage and Molecule Type Table 12 Inactive Products
• Wockhardt • Spero Therapeutics • Iterum Therapeutics • Sihuan Pharmaceuticals • Entasis Therapeutics • SuperTrans Medical • Locus Biosciences • Venatorx Pharmaceuticals • MerLion Pharmaceuticals • Allecra Therapeutics
  • PRICE
  • $1500
    $4500

Our Clients